LLY vs SARO · P/E 39, rev $22.97B vs P/E 31, rev $6.06B
Eli Lilly and Company (LLY) versus StandardAero, Inc. (SARO) — a side-by-side from cached financials, not a winner call.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David A. Ricks.
StandardAero, Inc. (SARO) is a aerospace & defense company listed on NYSE.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Latest reported SARO revenue for 2025-12-31 was $6.06B. Net income was $277.4M. Revenue was up 15.8% from 2024-12-31 to 2025-12-31. SARO currently screens at market cap $9.03B and trailing P/E 30.9.
LLY currently screens at market cap $991.62B and trailing P/E 39.5. SARO currently screens at market cap $9.03B and trailing P/E 30.9.
Not investment advice. Open the LLY and SARO stock pages for the full models.
Not investment advice.